|
The Cochrane Collaboration
Cochrane Reviews |
| Explore | New + Updated | Other languages |
|
 |
Pharmacological treatment for Kleine-Levin SyndromeOliveira MM, Conti C, Saconato H, Fernandes do Prado G
Bookmark this:
     more ...
SummaryPharmacological treatment for Kleine-Levin SyndromeKleine-Levin Syndrome (KLS) is a rare disorder which mainly affects adolescent men. It is characterized by recurrent episodes of hypersomnia (excessive sleepiness), hyperphagia (over eating) and abnormal behavior. The frequency and nature of the attacks can disrupt the individual's social, professional and family life. The cause of Kleine-Levin Syndrome is not known. Several treatments have been used, including stimulant, antiepileptic, antidepressant and antipsychotic drugs, with some benefit reported, but due to the rarity of the condition, long-term follow up of patients is difficult. The authors of this review aimed to identify and evaluate randomized controlled trials (RCTs) studying the effectiveness of pharmacological treatment for Kleine-Levin Syndrome. We were not able to find any RCTs. Good quality evidence is therefore lacking and therapeutic trials with a double-blind, placebo-controlled design are needed.
This is a Cochrane review abstract and plain language summary, prepared and maintained by The Cochrane Collaboration, currently published in The Cochrane Database of Systematic Reviews 2010 Issue 1, Copyright © 2010 The Cochrane Collaboration. Published by John Wiley and Sons, Ltd.. The full text of the review is available in The Cochrane Library (ISSN 1464-780X).
This version first published online:
April 15. 2009 AbstractBackgroundKleine-Levin Syndrome (KLS) is a rare disorder which mainly affects adolescent men. It is characterized by recurrent episodes of hypersomnia, usually accompanied by hyperphagia, cognitive and mood disturbances, abnormal behavior such as hypersexuality, and signs of dysautonomia. In 1990 the diagnostic criteria for Kleine-Levin Syndrome were modified in the International Classification of Sleep Disorders, where it was defined as a syndrome composed of recurring episodes of undue sleepiness lasting some days, which may or may not be associated with hyperphagia and abnormal behavior. The etiology of Kleine-Levin Syndrome remains unknown and several treatment strategies have been used. Some medications have been reported to provide some benefit for the treatment of Kleine-Levin Syndrome patients, but because of the rarity of the condition no long-term follow-up therapies have yet been described. ObjectivesThis review aimed to evaluate: 1. whether pharmacological treatment for Kleine-Levin Syndrome is effective and safe; and Search strategyWe obtained relevant trials from the following sources: the Cochrane Epilepsy Group Specialized Register (1 December 2007); the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 3, 2007); MEDLINE (1966 to December 2007); EMBASE (1980 to December 2007); LILACS (1982 to December 2007); reference lists of sleep medicine textbooks; review articles and reference lists of articles identified by the search strategies. Selection criteriaAll randomized controlled trials (RCTs) and quasi-randomized controlled trials looking at pharmacological interventions for Kleine-Levin Syndrome. We included both parallel group and cross-over studies. Data collection and analysisTwo review authors (MO and CC) extracted the data reported in the original articles. Main resultsNo studies met the inclusion criteria for this systematic review. Authors' conclusionsTherapeutic trials of pharmacological treatment for Kleine-Levin Syndrome, with a double-blind, placebo-controlled design are needed. |